Spotlight on opicapone as an adjunct to levodopa in parkinson’s disease: Design, development and potential place in therapy

Annus, L. Vécsei

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Parkinson’s disease (PD) is a progressive, chronic, neurodegenerative disease characterized by rigidity, tremor, bradykinesia and postural instability secondary to dopaminergic deficit in the nigrostriatal system. Currently, disease-modifying therapies are not available, and levodopa (LD) treatment remains the gold standard for controlling motor and nonmotor symptoms of the disease. LD is extensively and rapidly metabolized by peripheral enzymes, namely, aromatic amino acid decarboxylase and catechol-O-methyltransferase (COMT). To increase the bioavailability of LD, COMT inhibitors are frequently used in clinical settings. Opicapone is a novel COMT inhibitor that has been recently approved by the European Medicines Agency as an adjunctive therapy to combinations of LD and aromatic amino acid decarboxylase inhibitor in adult PD patients with end-of-dose motor fluctuations. We aimed to review the biochemical properties of opicapone, summarize its preclinical and clinical trials and discuss its future potential role in the treatment of PD.

Original languageEnglish
Pages (from-to)143-151
Number of pages9
JournalDrug Design, Development and Therapy
Volume11
DOIs
Publication statusPublished - 2017

Fingerprint

Levodopa
Parkinson Disease
Aromatic-L-Amino-Acid Decarboxylases
Catechol O-Methyltransferase
Hypokinesia
Tremor
Therapeutics
Neurodegenerative Diseases
Biological Availability
Chronic Disease
Clinical Trials
opicapone
Enzymes
Catechol O-Methyltransferase Inhibitors

Keywords

  • COMT inhibitors
  • Opicapone
  • Parkinson’s disease

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

@article{351322b579874f4abe11f3ba00bbe73b,
title = "Spotlight on opicapone as an adjunct to levodopa in parkinson’s disease: Design, development and potential place in therapy",
abstract = "Parkinson’s disease (PD) is a progressive, chronic, neurodegenerative disease characterized by rigidity, tremor, bradykinesia and postural instability secondary to dopaminergic deficit in the nigrostriatal system. Currently, disease-modifying therapies are not available, and levodopa (LD) treatment remains the gold standard for controlling motor and nonmotor symptoms of the disease. LD is extensively and rapidly metabolized by peripheral enzymes, namely, aromatic amino acid decarboxylase and catechol-O-methyltransferase (COMT). To increase the bioavailability of LD, COMT inhibitors are frequently used in clinical settings. Opicapone is a novel COMT inhibitor that has been recently approved by the European Medicines Agency as an adjunctive therapy to combinations of LD and aromatic amino acid decarboxylase inhibitor in adult PD patients with end-of-dose motor fluctuations. We aimed to review the biochemical properties of opicapone, summarize its preclinical and clinical trials and discuss its future potential role in the treatment of PD.",
keywords = "COMT inhibitors, Opicapone, Parkinson’s disease",
author = "Annus and L. V{\'e}csei",
year = "2017",
doi = "10.2147/DDDT.S104227",
language = "English",
volume = "11",
pages = "143--151",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Spotlight on opicapone as an adjunct to levodopa in parkinson’s disease

T2 - Design, development and potential place in therapy

AU - Annus,

AU - Vécsei, L.

PY - 2017

Y1 - 2017

N2 - Parkinson’s disease (PD) is a progressive, chronic, neurodegenerative disease characterized by rigidity, tremor, bradykinesia and postural instability secondary to dopaminergic deficit in the nigrostriatal system. Currently, disease-modifying therapies are not available, and levodopa (LD) treatment remains the gold standard for controlling motor and nonmotor symptoms of the disease. LD is extensively and rapidly metabolized by peripheral enzymes, namely, aromatic amino acid decarboxylase and catechol-O-methyltransferase (COMT). To increase the bioavailability of LD, COMT inhibitors are frequently used in clinical settings. Opicapone is a novel COMT inhibitor that has been recently approved by the European Medicines Agency as an adjunctive therapy to combinations of LD and aromatic amino acid decarboxylase inhibitor in adult PD patients with end-of-dose motor fluctuations. We aimed to review the biochemical properties of opicapone, summarize its preclinical and clinical trials and discuss its future potential role in the treatment of PD.

AB - Parkinson’s disease (PD) is a progressive, chronic, neurodegenerative disease characterized by rigidity, tremor, bradykinesia and postural instability secondary to dopaminergic deficit in the nigrostriatal system. Currently, disease-modifying therapies are not available, and levodopa (LD) treatment remains the gold standard for controlling motor and nonmotor symptoms of the disease. LD is extensively and rapidly metabolized by peripheral enzymes, namely, aromatic amino acid decarboxylase and catechol-O-methyltransferase (COMT). To increase the bioavailability of LD, COMT inhibitors are frequently used in clinical settings. Opicapone is a novel COMT inhibitor that has been recently approved by the European Medicines Agency as an adjunctive therapy to combinations of LD and aromatic amino acid decarboxylase inhibitor in adult PD patients with end-of-dose motor fluctuations. We aimed to review the biochemical properties of opicapone, summarize its preclinical and clinical trials and discuss its future potential role in the treatment of PD.

KW - COMT inhibitors

KW - Opicapone

KW - Parkinson’s disease

UR - http://www.scopus.com/inward/record.url?scp=85010285165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010285165&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S104227

DO - 10.2147/DDDT.S104227

M3 - Article

C2 - 28123288

AN - SCOPUS:85010285165

VL - 11

SP - 143

EP - 151

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -